Bioporto As Stock Performance
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and BioPorto are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days BioPorto AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, BioPorto is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 107.9 M | |
| Total Cashflows From Investing Activities | -412 K |
BioPorto |
BioPorto Relative Risk vs. Return Landscape
If you would invest (100.00) in BioPorto AS on December 5, 2025 and sell it today you would earn a total of 100.00 from holding BioPorto AS or generate -100.0% return on investment over 90 days. BioPorto AS is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than BioPorto, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BioPorto Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioPorto for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioPorto AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioPorto AS is not yet fully synchronised with the market data | |
| BioPorto AS has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 24.25 M. Net Loss for the year was (57.11 M) with profit before overhead, payroll, taxes, and interest of 15.04 M. | |
| BioPorto AS has accumulated about 86.72 M in cash with (64.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders |
BioPorto Fundamentals Growth
BioPorto Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BioPorto, and BioPorto fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioPorto Pink Sheet performance.
| Return On Equity | -0.88 | |||
| Return On Asset | -0.41 | |||
| Profit Margin | (2.50) % | |||
| Operating Margin | (2.82) % | |||
| Current Valuation | 106.91 M | |||
| Shares Outstanding | 334.68 M | |||
| Price To Book | 12.43 X | |||
| Price To Sales | 9.27 X | |||
| Revenue | 24.25 M | |||
| EBITDA | (58.6 M) | |||
| Cash And Equivalents | 86.72 M | |||
| Cash Per Share | 0.32 X | |||
| Total Debt | 10.42 M | |||
| Debt To Equity | 0.12 % | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (64.58 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 81.25 M | |||
About BioPorto Performance
By analyzing BioPorto's fundamental ratios, stakeholders can gain valuable insights into BioPorto's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioPorto has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioPorto has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioPorto AS, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company was founded in 2000 and is headquartered in Hellerup, Denmark. Bioporto operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 29 people.Things to note about BioPorto AS performance evaluation
Checking the ongoing alerts about BioPorto for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BioPorto AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioPorto AS is not yet fully synchronised with the market data | |
| BioPorto AS has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 24.25 M. Net Loss for the year was (57.11 M) with profit before overhead, payroll, taxes, and interest of 15.04 M. | |
| BioPorto AS has accumulated about 86.72 M in cash with (64.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing BioPorto's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioPorto's stock is overvalued or undervalued compared to its peers.
- Examining BioPorto's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioPorto's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioPorto's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioPorto's pink sheet. These opinions can provide insight into BioPorto's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioPorto Pink Sheet analysis
When running BioPorto's price analysis, check to measure BioPorto's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioPorto is operating at the current time. Most of BioPorto's value examination focuses on studying past and present price action to predict the probability of BioPorto's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioPorto's price. Additionally, you may evaluate how the addition of BioPorto to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |